Items tagged with Treatment
TB alone and with HIV co-infection: Treatment updates (post)
In patients with a history of tuberculosis (TB), the odds of residual pulmonary impairments are 2- to 3-fold higher compared with individuals with no TB history, with especially high rates in patients with multidrug-resistant TB.1 HIV has been identified as an independent risk factor for predominantly obstructive impairment in lung function. However, there is a dearth of research regarding lung function in HIV-associated TB because patients with HIV are frequently excluded from relevant studies, despite the fact that an estimated 40% of deaths in people with HIV have been attributed to TB.1,2
New, shorter treatment to prevent TB to be rolled out in five high-burden TB countries (post)
Three-month regimen expected to prevent TB in those at highest risk of developing the disease, including people living with HIV and children under the age of five.
Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking (post)
"Ultimately, high-quality evidence to guide regulatory and policy decision-making must come from adequately designed (and funded) RCTs [randomized controlled trials]–the highest attainable standard of medical evidence, which we owe to patients affected by drug-resistant tuberculosis to strive for and maintain."
If J&J really wants to support nurses, it should make the TB drug bedaquiline affordable (post)
As nurses who worked in 5B, the first U.S. hospital ward dedicated HIV/AIDS, which opened in San Francisco General Hospital in 1983, we have been directly affected in profound ways by the disease and its opportunistic infections.
TB antibacterial courses ineffective in minimizing antibiotic use (post)
The current trials testing broad-spectrum antibiotics before treating tuberculosis are not aligned with protocols designed to minimize the use of antibiotics, according to a paper published in The Lancet Infectious Diseases.
Increased access to pretomanid/BPaL regimen (post)
27 May 2020, Geneva, Switzerland – On 28 October 2019, the Stop TB Partnership announced the addition of pretomanid to the Global Drug Facility (GDF) catalog as part of a BPaL regimen containing bedaquiline, pretomanid, and linezolid. GDF supplies pretomanid to countries in accordance with WHO recommendations for people with extensively drug-resistant TB (XDR-TB) when used under operational research conditions.
Deltyba® (delamanid) approved in the Russian Federation for the treatment of pulmonary MDR-TB (post)
-- Deltyba® (delamanid) — an essential medicine according to the World Health Organization [1] — is now available in Russia for difficult-to-treat MDR-TB patients.
-- Deltyba® (delamanid), developed by Otsuka Pharmaceutical Co., Ltd. based in Japan, is commercialized in Russia by the R-Pharm group of companies.
U.S. FDA approves new pediatric formulation of SIRTURO® (bedaquiline) as part of combination therapy to treat children with pulmonary multidrug-resistant TB (post)
NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided.
Following US FDA approval, child-friendly bedaquiline available from Stop TB Partnership's GDF Pediatric DR-TB Initiative (post)
11 June 2020, Geneva, Switzerland– The Stop TB Partnership’s Global Drug Facility (GDF) today announced the addition of child-friendly bedaquiline 20 mg tablets to the GDF Pediatric DR-TB Initiative. The US FDA approval of the medicine, on 27 May 2020, marks a new milestone for all-oral DR-TB regimens in children who are older than 5 years of age and weighing more than 15 kilograms. These children will now benefit from the same optimized treatments being provided to their parents – no more injections for anyone.
High price excludes patients from better treatment for drug-resistant TB (post)
NAIROBI — Sheila Baraza, a 30-year-old resident of Ruaka, a city to the northwest of Nairobi, unsuccessfully fought back tears as she recalled the pain of seeking and then undertaking a two-year treatment for drug-resistant tuberculosis.
Page 53 of 106 · Total posts: 0
←First 52 53 54 Last→